EyeYon Medical Expands into China with New Subsidiary
Comunicato Precedente
Comunicato Successivo
"We are incredibly excited to announce the establishment of our new subsidiary, a significant step in strengthening our commitment to the Chinese market," said Nahum Ferera, CEO. "This expansion allows us to directly address the unmet needs within the region and significantly intensify our growth trajectory."
The new subsidiary will focus on several key areas to ensure its success in the market. These include:
EyeYon Medical's commitment to China extends beyond simply establishing a subsidiary. The company is deeply invested in fostering long-term relationships with local healthcare professionals, research institutions, and government agencies. This collaborative approach ensures that EyeYon Medical's technologies are integrated seamlessly into the existing healthcare infrastructure, maximizing their impact on patient care. The company is also actively involved in supporting local communities through educational initiatives and philanthropic activities, further strengthening its ties with the region.

EyeYon Medical is revolutionizing eye care with EndoArt®, the world's first synthetic corneal implant for chronic edema. A groundbreaking alternative to donor tissue, EndoArt® is always available, rejection-free, and cost-effective. This innovative implant restores corneal clarity and vision, offering new hope to millions worldwide.
Media Contact: [email protected]
View original content:https://www.prnewswire.co.uk/news-releases/eyeyon-medical-expands-into-china-with-new-subsidiary-302367587.html

Ufficio Stampa
PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom